PLAUR and colorectal carcinoma: We investigated the ability of new small molecules targeting uPAR-VN binding site, C6 and C37, previously identified and validated by Rea and colleagues, to inhibit uPAR-mediated functions in RAS mutated NSCLC and CRC cell lines.